ICU sedation, delirium & recovery
Haloperidol for the treatment of delirium in critically ill patients: an updated systematic review with meta-analysis and trial sequential analysis
Authors' conclusion
Haloperidol may reduce mortality and likely result in little to no change in the occurrence of SAEs/SARs compared with placebo in critically ill patients with delirium.
Study context
- Population
- Critically ill patients with delirium15 comparisons
- Participants
- 2,200 patients · 11 RCTs
- Comparison
- Haloperidol vs placebo or any comparator
- Outcome
- All-cause mortality and proportion of patients with ≥1 serious adverse events or reactions (SAEs/SARs)
Methodological detailstrial sequential analysis, updated systematic review
- Trial sequential analysis
- Updated systematic review
Pooled result
As reported in the abstract
Haloperidol vs PlaceboRelative risk (96.7% CI)
Mortality; I2 = 0%; moderate-certainty evidence
0.89(0.77–1.03)
SAEs/SARs; I2 = 18%; low-certainty evidence
0.94(0.81–1.10)
Further pooled results
Days alive without delirium or coma
- No difference (moderate-certainty evidence)
Other secondary outcomes and comparators other than placebo
- Sparse data
Safety
| Outcome | RR (96.7% CI) | |
|---|---|---|
| Patients with ≥1 SAEs/SARsI2 = 18%; low-certainty evidence | 0.94 (0.81–1.10) | |
| 0.512Relative risk (log scale) |
Original publication
Haloperidol for the treatment of delirium in critically ill patients: an updated systematic review with meta-analysis and trial sequential analysis. Crit Care. Published 26 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →